GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Hyperglycemia strongly affects endothelial function and activation, which in turn increases the risk of atherosclerotic cardiovascular disease. Among pharmacotherapies aimed at lowering blood glucose levels, glucagon-like peptide 1 receptor agonists (GLP-1RA) represent a class of drugs involved in the improvement of the endothelium damage and the progression of cardiovascular diseases. They show antihypertensive and antiatherosclerotic actions due at least in part to direct favorable actions on the coronary vascular endothelium, such as oxidative stress reduction and nitric oxide increase. However, cumulative peripheral indirect actions could also contribute to the antiatherosclerotic functions of GLP-1/GLP-1R agonists, including metabolism and gut microbiome regulation. Therefore, further research is necessary to clarify the specific role of this drug class in the management of cardiovascular disease and to identify specific cellular targets involved in the protective signal transduction. In the present review, we provide an overview of the effects of GLP-1RAs treatment on cardiovascular disease with particular attention on potential molecular mechanisms involving endothelium function on formation and progression of atherosclerotic plaque.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“Intestinal L cell-derived GLP-1 is a postprandial peptide that plays a critical role in the con-trol of blood glucose level by increasing insulin secretion in pancreatic β cells and suppressing glucagon release [8].”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 2×
“GLP-1R is expressed in several cells involved in the pathogenesis of atherosclerosis, including endothelium and macrophages [16, 17]; 3.”
BackgroundZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · cited 1×
“The most evident reduction appears to be associated with atherosclerotic pathways suggesting anti-atherogenic properties of GLP-1RA [12, 13].”
BackgroundArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“The data suggest that exendin-4 markedly reduced monocyte/macrophage accumulation in the vascular wall at least in part by suppressing the inflammatory response in macrophages through activation of the cAMP/PKA pathway [32].”
BackgroundRakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 1×
“Endogenous GLP-1 has a very short elimination half-life of 1.5 min after intravenous administration due to rapid degradation by the enzyme dipeptidyl peptidase (DPP4) [9].”
BackgroundInfluentialCirculation and Degradation of GIP and GLP-1
Deacon, C. F. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826160 · Cited by 299
Helmstädter, J., Frenis, K., Filippou, K., Grill, A., Dib, M., Kalinovic, S., Pawelke, F., Kus, K., Kröller-Schön, S., Oelze, M., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000615456.97862.30 · Cited by 283 · cited 1×
“…the vascular protective effects were abolished in global Glp1r-/- mice and in mice with selective disruption of GLP-1R expression in EC but not in the myeloid lineage, indicating that endothelial GLP-1R mediates cardiovascular protection by the GLP-1RA liraglutide-independent glycemic control [35].”
BackgroundEffects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217 · cited 1×
“GLP-1R acts in many pathways involved in the regulation of endothelial function [15]; 2.”
BackgroundBalestrieri, M. L., Rizzo, M. R., Barbieri, M., Paolisso, P., D’Onofrio, N., Giovane, A., Siniscalchi, M., Minicucci, F., Sardu, C., D’Andrea, D., et al. (2015) · Diabetes · doi:10.2337/db14-1149 · Cited by 196 · cited 1×
“The relevance of the obtained results is confirmed by the evidence that compared with non-GLP-1 therapy-treated plaques, GLP-1 therapy-treated plaques presented greater SIRT6 expression and collagen content, and less inflammation and oxidative stress, indicating a more stable plaque phenotype [23].”
Result
Cited by
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Korakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae122 · Cited by 18
“The endothelium may present a direct target for GLP-1RAs, as it is suggested by the presence of the corresponding receptor in endothelial cells and macrophages, and by several in vitro studies where a protective role of GLP-1RA treatment has been demonstrated [9].”
BackgroundWaqas, S. A., Ali, D., Afridi, M. K., Siddiqui, H. F., Nazir, A., Greene, S. J., & Khan, M. S. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.105981 · Cited by 11
Metadata
- Authors
- Menghini, R., Casagrande, V., Rizza, S., & Federici, M.
- Venue
- Acta Diabetologica
- Published
- 2023-07-04
- Volume
- 60
- Issue
- 11
- Pages
- 1441-1448
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W4383058774
- Cited by
- 47
- References
- 17
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform? https://app.cochat.ai/papers/10.1007/s00592-023-02124-w
- The paper
- Menghini, R., Casagrande, V., Rizza, S., & Federici, M. (2023). GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform? Acta Diabetologica. https://doi.org/10.1007/s00592-023-02124-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.